[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368956-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368956-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prss22-as-a-novel-prognostic-and-immune-regulatory-biomarker-in-pancancer-multiomics-analysis","PRSS22 as a novel prognostic and immune regulatory biomarker in PanCancer multiomics analysis","","Serine proteases drive tumorigenesis, yet the pan-cancer role of PRSS22 remained unclear. This study integrates multi-omics and clinical data across 33 cancer types using TCGA, HPA, and cBioPortal. Analyses cover expression (cancer vs. normal), prognosis via overall survival, immune microenvironment characterization, functional enrichment, and genomic alterations. PRSS22 shows cancer-type specificity, with overexpression in 10 and downregulation in 4 cancers, and higher tumor expression linked to worse survival in multiple cancers. Associations with immune infiltration and pathway enrichment support PRSS22 as a context-dependent biomarker with diagnostic/prognostic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prss22-as-a-novel-prognostic-and-immune-regulatory-biomarker-in-pancancer-multiomics-analysis/368956/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prss22-as-a-novel-prognostic-and-immune-regulatory-biomarker-in-pancancer-multiomics-analysis/368956.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What datasets and platforms are used to study PRSS22 across cancers?","Question",{"text":63,"@type":64},"The analysis uses multi-omics and clinical data from TCGA, HPA, and cBioPortal, including transcriptomic and protein expression resources.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PRSS22 expression relate to cancer prognosis?",{"text":68,"@type":64},"Elevated tumor PRSS22 expression is independently associated with worse overall survival in multiple cancers, including KIRC, LIHC, LUAD, and SKCM.",{"name":70,"@type":61,"acceptedAnswer":71},"How is PRSS22 connected to the tumor immune microenvironment?",{"text":72,"@type":64},"PRSS22 levels show associations with immune microenvironment features, and related/co-expressed genes are enriched in cancer-relevant biological processes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368956,1790879192,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPRSS22 as a novel prognostic and immune regulatory biomarker in PanCancer multiomics analysis  \nTao Jiang1,2, Jialin Liu1,4, Hao Chen1,2,4, Fangyu Lin1,2, XiaojiaoWeng1,2, Qing Liu1,2, Han Wang1,2, Bin Du1,2, Xinli Wang1,2, Xiaoyan Lin1,2 & Wenyu Gao3􀀍  \nSerine proteases are key mediators oftumorigenesis; however, the pan-cancer significance of PRSS22 remains poorly defined. This study comprehensively analyzes the multi-omics landscape and clinical relevance of PRSS22 across 33 cancer types using data from TCGA, HPA, and cBioPortal. We performed systematic analyses, including expression profiling (cancer vs. normal), prognosis (overall survival), characterization of the immune microenvironment, functional enrichment, and assessment of genomic alterations. PRSS22 expression demonstrated significant cancer-type specificity, with frequent overexpression observed in 10 cancer types and downregulation in 4 cancer types (p \u003C 0.05) . Notably, elevated tumor expression levels of PRSS22 were independently associated with worse overall survival in multiple cancers, specifically KIRC, LIHC, LUAD, and SKCM (p \u003C 0.05) . Despite showing downregulation atthe mRNA level in KIRC, LIHC, and SKCM cancer cell lines as validated by qPCR, higher tumor tissue PRSS22 expression in patient cohorts of these cancers remained strongly associated with poor prognosis—a paradox suggesting potential non-cell-autonomous roles. Furthermore, PRSS22 levels showed associations with the tumor immune microenvironment. Functional enrichment analyses indicated that PRSS22 co-expressed/related genes are enriched in diverse biological processes relevant to cancer. Our pan-cancer analysis establishes PRSS22 as a multifaceted biomarker with prognostic value and links to tumor immunity, highlighting its complex, context-dependent roles across malignancies. These findings provide a crucial foundation for elucidating PRSS22’s mechanisms and assessing its potential for diagnostic/prognostic applications.  \nKeywords PRSS22, Pan-Cancer analysis, Tumor immune microenvironment, Multi-omics, Serine protease  \nCancer remains a leading cause of global mortality, with tumor heterogeneity and dysregulated molecular pathways posing significant challenges1. Serine proteases, a class of enzymes involved in extracellular matrix remodeling, immune modulation, and cellular signaling, have emerged as critical regulators of oncogenesis and tumor progression2,3. The PRSS22 gene, mapping to chromosome 16p13.3, was initially identified as a member of the serine protease family. It is primarily expressed in airway epithelial cells under physiological conditions and is involved in extracellular matrix remodeling, immune regulation, and cellular signaling4,5. Among these, PRSS22 has been implicated in tumorigenesis through its potential roles in proteolytic cascades and microenvironmental interactions6. However, a comprehensive pan-cancer analysis of PRSS22—incorporating its expression patterns, prognostic significance, and mechanistic connections with immune infiltration—has not been thoroughly investigated, thus constraining its potential clinical application as a biomarker or therapeutic target.  \nRecent advances in multi-omics databases, including The Cancer Genome Atlas (TCGA)7 and the Human Protein Atlas (HPA)8, provide unprecedented opportunities to decode cancer-associated genes across diverse malignancies. While preliminary studies have linked PRSS22 to specific cancers6,9, its pan-cancer expression profile, mutation landscape, and interactions with tumor-infiltrating immune cells remain poorly characterized. Furthermore, conflicting reports on the tissue-specific roles underscore the need for systematic investigations that integrate genomic, proteomic, and clinical datasets10.  \n1Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou 350001, People’s Republic of China. 2Fujian Provin","cbCaijQRwMWenLOd","https://ap.wps.com/l/cbCaijQRwMWenLOd","pdf",8412401,12,"English","# Materials and methods\n## Data acquisition and processing\n## Expression and clinical association analyses\n## Immune microenvironment characterization\n## Functional enrichment and PPI analyses\n## Genomic alteration and mutation burden assessment","[{\"question\":\"What datasets and platforms are used to study PRSS22 across cancers?\",\"answer\":\"The analysis uses multi-omics and clinical data from TCGA, HPA, and cBioPortal, including transcriptomic and protein expression resources.\"},{\"question\":\"How does PRSS22 expression relate to cancer prognosis?\",\"answer\":\"Elevated tumor PRSS22 expression is independently associated with worse overall survival in multiple cancers, including KIRC, LIHC, LUAD, and SKCM.\"},{\"question\":\"How is PRSS22 connected to the tumor immune microenvironment?\",\"answer\":\"PRSS22 levels show associations with immune microenvironment features, and related/co-expressed genes are enriched in cancer-relevant biological processes.\"}]","PRSS22 as a novel prognostic and immune regulatory biomarker in PanCancer multiomics analysis | PDF",1790179779,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/853e91ba5cd4c5570d69dc38f868019c.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2ba0de53838c30470bbf69b982c962e.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abc70be971b425b7b39035ef32ef80f5.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4b626b8b329166b02ae5da7060b0a12.webp",980,1287]